Mounjaro articles: what the research and regulators actually say

What does the trial literature actually show about how well Mounjaro works?

The cornerstone study in the tirzepatide evidence base is SURMOUNT-1, a 72-week randomised controlled trial involving 2,539 adults living with obesity but without type 2 diabetes. Participants taking the 15mg dose lost an average of around 20–21% of their body weight, with some analyses reaching approximately 22.5%. Those are large numbers for a pharmacological intervention, and they drew considerable attention when the paper landed in the New England Journal of Medicine.

Then came SURMOUNT-5, a direct head-to-head trial published in the NEJM in 2025, comparing tirzepatide against semaglutide 2.4mg (the standard Wegovy dose) in 751 adults with obesity and no diabetes, over 72 weeks. Tirzepatide produced greater average weight reduction. That head-to-head data matters, because most earlier comparisons were indirect, statisticians comparing results across separate trials run at different times with different populations. A proper randomised comparison is a stronger signal.

The honest caveat worth carrying from any trial is that averages describe groups, not individuals. Responses vary. If you want a closer look at what the clinical literature says about how and why the medicine produces these results, our tirzepatide review article walks through the evidence in detail. That's the conversation to have with a prescriber.

You can read more about the mechanism and dosing schedule on the tirzepatide overview page.

What have UK regulators and NICE actually concluded?

A question our prescribers hear most weeks is some version of: "Is Mounjaro actually approved, or is it just something people are getting privately?" Both, is the honest answer.

The MHRA granted Mounjaro its UK marketing authorisation for weight management, covering adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. It carries a Black Triangle (▼), meaning the MHRA collects additional safety data during early use, standard for newer medicines, not a cause for alarm.

NICE then evaluated the evidence and published Technology Appraisal 1026 in December 2024, recommending tirzepatide for NHS use in England. The NHS rollout is phased: from June 2025, eligibility opened for people with a BMI of 40 or above and four or more of a defined set of comorbidities; a second cohort with BMI 35–39.9 became eligible in June 2026. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reduced by 2.5 kg/m². Full details of NICE's recommendation are in NICE TA1026.

Private prescribing follows the licensed criteria in the SmPC rather than the NHS phased criteria, which is why some people access treatment privately before their NHS cohort becomes eligible.

What does the medical literature say about Mounjaro's side effects?

The side-effect profile documented in the tirzepatide articles and trial data is led by the gut. Nausea, loose stools, constipation, indigestion, belching and fatigue are the most commonly reported effects. They tend to peak after a dose starts or increases, then ease over days to a couple of weeks for most people. That's why the treatment ladder begins at 2.5mg: the starter dose exists to let the digestive system adjust before the prescriber moves the dose higher.

Less common but more serious effects described in the literature include acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update drawing attention to this risk across the GLP-1 medicine class: the symptom to act on is severe, persistent stomach pain that spreads to the back, with or without vomiting. That's a reason to get same-day medical help, not to wait and see. You can report suspected side effects to the MHRA via the Yellow Card scheme, patients can do this directly, not just clinicians.

For anyone specifically curious about muscle-related symptoms that appear in some published accounts, we've pulled together what the evidence shows on the Mounjaro and muscle soreness page and in more detail on how Mounjaro affects muscles.

Who does the published evidence say Mounjaro is suitable for?

The licensed eligibility criteria draw from the same clinical rationale as the trial design: adults, BMI 30 or above (or 27 or above with a relevant condition), who are also making changes to diet and activity. The medicine is studied and licensed as an adjunct to lifestyle changes, not a replacement for them. That framing matters when reading tirzepatide articles that lead with a weight-loss figure without mentioning the trial's lifestyle-support component.

The evidence is clear that Mounjaro is not suitable during pregnancy, breastfeeding, or when actively trying to conceive. It is not licensed for people under 18. Certain medical histories (including medullary thyroid carcinoma, multiple endocrine neoplasia type 2 and some gastrointestinal conditions) require careful prescriber review before treatment. The full contraindication and caution list sits in the SmPC on the eMC and in the Patient Information Leaflet that comes with every pen.

If you're weighing up the cost of private treatment alongside what the evidence suggests about likely benefit, our Mounjaro cost page gives an honest breakdown of how UK private pricing works. And if you want the fullest picture of Mounjaro as a treatment, the Mounjaro overview covers the mechanism, the journey through doses, and what clinical supervision looks like in practice.

When you're ready to find out whether you'd be suitable, check your eligibility through a free consultation with our prescribers, reviewed the same day by a GPhC-registered Independent Prescriber, not a screening algorithm.